AKERS BIOSCIENCES FEATURES ON GLOBAL MEDIA

AKERS BIOSCIENCES FEATURES ON GLOBAL BROADCAST & ONLINE MEDIA

Executive Chairman appeared on Fox Business nationwide & Bloomberg Europe, UK and Asia

THOROFARE, N.J., September 16, 2014 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, was featured on "The RedChip Money Report: Small Stocks Big Money" television program which was televised on Fox Business nationwide as well as Bloomberg Europe, UK and Asia. A recording of the globally transmitted interview regarding Akers Biosciences' business can be viewed here: http://youtu.be/5ymviBu1kno.

In addition, Dr. Akers was featured on IGPlayer, the on-demand video platform belonging to IG Group, a global leader in online trading. A recording of the interview can be viewed here: http://youtu.be/8M3K2t2VqEs.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences (the "Company") develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Raymond F. Akers, Jr. PhD

Executive Chairman of the Board

Akers Biosciences, Inc.

Tel. +1 856 848 8698

Brendan Hopkins

RedChip Companies, Inc. (US Investor Relations)

Tel. +1 407 644 4256 x134

finnCap (UK Nominated Adviser and Broker)

Geoff Nash / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel: +44 (0)20 7220 0500

Ben Simons / Alexandra Roper

Vigo Communications (UK Investor Relations)

Tel. +44 (0)20 7016 9570

Email. [email protected]